These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35267618)

  • 101. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
    Wang Y; Geldres C; Ferrone S; Dotti G
    Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
    [TBL] [Abstract][Full Text] [Related]  

  • 102. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 103. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
    Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
    J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
    [TBL] [Abstract][Full Text] [Related]  

  • 104. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 105. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia.
    Hoffmeister LM; Orhan E; Walter C; Niktoreh N; Hanenberg H; von Neuhoff N; Reinhardt D; Schneider M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638301
    [No Abstract]   [Full Text] [Related]  

  • 108. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Casali PG; Blay JY; Abecassis N; Bajpai J; Bauer S; Biagini R; Bielack S; Bonvalot S; Boukovinas I; Bovee JVMG; Boye K; Brodowicz T; Buonadonna A; De Álava E; Dei Tos AP; Del Muro XG; Dufresne A; Eriksson M; Fedenko A; Ferraresi V; Ferrari A; Frezza AM; Gasperoni S; Gelderblom H; Gouin F; Grignani G; Haas R; Hassan AB; Hindi N; Hohenberger P; Joensuu H; Jones RL; Jungels C; Jutte P; Kasper B; Kawai A; Kopeckova K; Krákorová DA; Le Cesne A; Le Grange F; Legius E; Leithner A; Lopez-Pousa A; Martin-Broto J; Merimsky O; Messiou C; Miah AB; Mir O; Montemurro M; Morosi C; Palmerini E; Pantaleo MA; Piana R; Piperno-Neumann S; Reichardt P; Rutkowski P; Safwat AA; Sangalli C; Sbaraglia M; Scheipl S; Schöffski P; Sleijfer S; Strauss D; Strauss SJ; Hall KS; Trama A; Unk M; van de Sande MAJ; van der Graaf WTA; van Houdt WJ; Frebourg T; Gronchi A; Stacchiotti S;
    Ann Oncol; 2022 Jan; 33(1):20-33. PubMed ID: 34560242
    [No Abstract]   [Full Text] [Related]  

  • 109. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
    Uranowska K; Samadaei M; Kalic T; Pinter M; Breiteneder H; Hafner C
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34318902
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma.
    Dai D; Xie L; Shui Y; Li J; Wei Q
    Front Genet; 2021; 12():620705. PubMed ID: 33597971
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
    Chantharasamee J; Adashek JJ; Wong K; Eckardt MA; Chmielowski B; Dry S; Eilber FC; Singh AS
    Curr Treat Options Oncol; 2021 Jan; 22(1):9. PubMed ID: 33400014
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma.
    Dufresne A; Lesluyes T; Ménétrier-Caux C; Brahmi M; Darbo E; Toulmonde M; Italiano A; Mir O; Le Cesne A; Le Guellec S; Valentin T; Chevreau C; Bonvalot S; Robin YM; Coindre JM; Caux C; Blay JY; Chibon F
    Oncoimmunology; 2020 Jul; 9(1):1792036. PubMed ID: 32923153
    [TBL] [Abstract][Full Text] [Related]  

  • 114. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
    Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
    Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
    [TBL] [Abstract][Full Text] [Related]  

  • 115. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
    Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
    [TBL] [Abstract][Full Text] [Related]  

  • 116. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
    Harrer DC; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.
    Pantaleo MA; Tarantino G; Agostinelli C; Urbini M; Nannini M; Saponara M; Castelli C; Stacchiotti S; Fumagalli E; Gatto L; Santini D; De Leo A; Marafioti T; Akarca A; Sabattini E; Pession A; Ardizzoni A; Indio V; Astolfi A
    Oncoimmunology; 2019; 8(9):e1617588. PubMed ID: 31428517
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
    Bertucci F; Finetti P; Simeone I; Hendrickx W; Wang E; Marincola FM; Viens P; Mamessier E; Ceccarelli M; Birnbaum D; Bedognetti D
    Br J Cancer; 2018 Nov; 119(11):1383-1391. PubMed ID: 30353048
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
    Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
    Front Immunol; 2017; 8():1911. PubMed ID: 29375561
    [TBL] [Abstract][Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.